Legal & General Group
NVLN

Legal & General Group’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Legal & General Group’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,224
Closed -$8K – 3429
2018
Q1 		$8K Hold
2,224
– – ﹤0.01% 3234
2017
Q4 		$7K Hold
2,224
– – ﹤0.01% 3253
2017
Q3 		$16K Hold
2,224
– – ﹤0.01% 3225
2017
Q2 		$21K Buy
+2,224
New +$21.4K ﹤0.01% 3184

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Legal & General Group's NVLN Position: Q2 2018 in Review

Legal & General Group sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2018, closing a stake of 2,224 shares — an estimated $8K sold.

Legal & General Group first reported a position in NVLN in Q2 2017 and held it in 4 quarters. The position peaked at $21K in Q2 2017. 53 funds tracked by Wall St. Rank hold NVLN as of Q2 2018.

  • Legal & General Group reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2018 after selling out during the quarter.
  • Legal & General Group sold 2,224 Novelion Therapeutics Inc. Common Shares shares in Q2 2018, an estimated $8K.
  • Legal & General Group first reported a position in Novelion Therapeutics Inc. Common Shares in Q2 2017 and held it in 4 quarters.
  • Legal & General Group's Novelion Therapeutics Inc. Common Shares position peaked at $21K in Q2 2017.
  • 53 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2018.

Based on Legal & General Group's 13F filing for Q2 2018, filed 10 Aug 2018.